MVA-based vaccine candidates encoding the native or prefusion-stabilized 
SARS-CoV-2 spike reveal differential immunogenicity in humans

Mayer, Leonie; Weskamm, Leonie M.; Fathi, Anahita; Kono, Maya; Heidepriem, Jasmin; Krähling, Verena; Mellinghoff, Sibylle C.; Ly, My Linh; Friedrich, Monika; Hardtke, Svenja; Borregaard, Saskia; Hesterkamp, Thomas; Löffler, Felix F.; Volz, Asisa; Sutter, Gerd; Becker, Stephan; Dahlke, Christine; Addo, Marylyn M.

doi:10.1038/s41541-023-00801-z

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans

MPS-Authors

/persons/resource/persons227662

Heidepriem, Jasmin
Felix Löffler, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons202218

Löffler, Felix F.
Felix Löffler, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

Article.pdf
(出版社版), 4MB

付随資料 (公開)

There is no public supplementary material available

引用

Mayer, L., Weskamm, L. M., Fathi, A., Kono, M., Heidepriem, J., Krähling, V., Mellinghoff, S. C., Ly, M. L., Friedrich, M., Hardtke, S., Borregaard, S., Hesterkamp, T., Löffler, F. F., Volz, A., Sutter, G., Becker, S., Dahlke, C., & Addo, M. M. (2024). MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans. npj Vaccines, 9(1):. doi:10.1038/s41541-023-00801-z.

引用: https://hdl.handle.net/21.11116/0000-000E-538C-7

要旨

In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine candidates, MVA-SARS-2-S and MVA-SARS-2-ST, encoding the native and the prefusion-stabilized SARS-CoV-2 spike protein, respectively. MVA-SARS-2-ST was more immunogenic than MVA-SARS-2-S, but both were less immunogenic compared to licensed mRNA- and ChAd-based vaccines in SARS-CoV-2 naïve individuals. In heterologous vaccination, previous MVA-SARS-2-S vaccination enhanced T cell functionality and MVA-SARS-2-ST boosted the frequency of T cells and S1-specific IgG levels when used as a third vaccination. While the vaccine candidate containing the prefusion-stabilized spike elicited predominantly S1-specific responses, immunity to the candidate with the native spike was skewed towards S2-specific responses. These data demonstrate how the spike antigen conformation, using the same viral vector, directly affects vaccine immunogenicity in humans.